results in reduced A␤ generation in cell-based models ish (K670M/N671L) mutations under the regulatory control of the murine Thy-1 promoter (mThy1-hAPP 751 ) of AD and in primary neurons (Puglielli et al., 2001) . In (Rockenstein et al., 2001) . These animals develop departicular, we showed that two ACAT inhibitors, CPtectable plaques in the neocortex and hippocampus at 113,818 and Dup128, inhibited A␤ production by up the ages of 4 and 6 months, respectively, and show to 50%.
memory deficits starting at 6 months of age. Given our Here, we used the ACAT inhibitor CP-113,818 in a prior observations that CP-113,818 reduced A␤ generatransgenic mouse model of AD to assess whether ACAT tion and not clearance, we used relatively young hAPP is a potential target for antiamyloid therapy in patients mice to minimize initial A␤ deposition. hAPP mice (n ϭ affected by AD. 12) at 4.5 months of age were administered 60 dayrelease biopolymer pellets containing 13 mg of CPResults 113,818 (7.2 mg/kg/day), while age-matched animals were implanted with placebo pellets (n ϭ 12). Recent CP-113,818 is a fatty acid anilide derivative designed to reports have shown that female mice have higher levels mimic the acyl-CoA substrate of ACAT and a potent of A␤ and amyloid pathology than age-matched males ACAT inhibitor in vitro, cell culture, and animals ( that lovastatin may function in a gender-specific manner in reducing mouse brain cholesteryl-ester levels, we ini- (Park et al., 2003) . Therefore, we included similar numtially treated nontransgenic animals with the ACAT inhibbers of male and female animals in both placebo and itor. Most ACAT inhibitors are poorly absorbed when CP-113,818 groups to detect possible gender-specific administered orally and are quickly turned over in the effects of the inhibitor in our mouse model. Following 4 blood or tissues (Marzetta et al., 1994) . To minimize days of Morris water maze (MWM) tests, the animals daily fluctuations in serum CP-113,818 levels in mice, were sacrificed at day 57 to ensure continued presence we delivered the inhibitor via implantable slow-release of the inhibitor. At 7.2 mg/kg/day of CP-113,818, there biopolymer pellets. Pellets containing CP-113,818 were was no histologic evidence of toxicity found in adrenal inserted surgically under dorsal skin to allow for continucortical cells, a potential class-related effect of ACAT ous and controlled release of the active compound over inhibitors ( Figure 1B ). Serum total cholesterol and liver an established period of time with effectively zero-order free cholesterol/cholesteryl-esters were reduced to levkinetics (Innovative Research of America). Eighteen nonels similar to those previously observed in nontranstransgenic mice at 3 months of age received 21 daygenic animals ( Figures 1A and 1C) . It is noteworthy that release biopolymer pellets containing 0, 0.2, 1.6, 3.2, liver cholesteryl-ester levels decreased by 87% (p Ͻ 4.8, and 7.1 mg/kg/day of CP-113,818 (n ϭ 3 per dose; 0.0001) in hAPP mice treated for 2 months with CP- Figure 1A ). The highest dose that was used in these 113,818 ( Figure 1C ). Taken together, these experiments studies was far below the tolerated dose of 150 mg/kg/ demonstrated that 2 months of CP-113,818 treatment day for rats, even allowing for relatively low bioavailabileffectively reduced cholesteryl-ester levels of hAPP ity in these animals (Marzetta et al., 1994) . CP-113,818 mice in the absence of adrenal toxicity. The tissue re-(7.1 mg/kg/day) reduced total cholesterol levels by 29% quirements for assessment of A␤ burden in the brains (p Ͻ 0.007) in the serum, in the absence of any evident of these animals precluded direct examination of their effect on food consumption and body weight (Figure brain cholesteryl-ester levels. 1A; data not shown). Hepatic free cholesterol and Brain plaque load was evaluated by thioflavin S and cholesteryl-esters were also decreased in a doseimmunohistochemical stainings (Figure 2 ). Thioflavin dependent manner by up to 37% (p Ͻ 0.03) and 93% S-positive plaques were barely detectable in the cortex (p Ͻ 0.0004), respectively ( Figure 1A ). As expected, CPof hAPP mice at 6.5 months of age and absent in CP-113,818 had no effect on free cholesterol levels in the 113,818-treated animals ( Figure 2A Figure 1A) . Thus, mice, contained significant numbers of A␤ deposits only these data indicate that 7.1 mg/kg/day of CP-113,818 in female but not in male animals ( Figure 2B and Suppleis effective in markedly reducing cholesteryl-ester levels mental Figure S2 at http://www.neuron.org/cgi/content/ in the brains of nontransgenic mice. full/44/2/227/DC1). In the cortices of all animals tested, To characterize the effect of CP-113,818 treatment CP-113,818 treatment reduced plaque numbers by 88% on AD-like pathology, we used hAPP mice that express (p Ͻ 0.0000016). Importantly, when the two genders were considered separately, plaque numbers were rehuman APP 751 containing the London (V717I) and Swed- Figure 3A ). Imporence in the A␤ 1-42 /A␤ 1-40 ratio ( Figure 3A ). Since brain extracts were obtained from entire hemispheres includtantly, soluble A␤ levels were also decreased in the initial TBS fraction, with A␤ 1-42 showing a significant 34% ing cortices and hippocampi, the difference between male and female A␤ levels at this age was accentuated reduction (p Ͻ 0.0014). This decrease was statistically significant in both genders. Soluble A␤ 1Ϫ40 levels were by the slowly developing amyloid pathology in male hippocampi (see Figure 2B ). When analyzed according to close to the limit of detection, but a trend toward decrease was observed (20%) in all animals, significant gender, only female "insoluble" A␤ was sufficiently elevated to obtain a highly significant decrease by CPonly in males ( Figure 3B) . Thus, three different methods To analyze the effect of CP-113,818 treatment on cogtreated male nontransgenic animals performed better than the placebo-treated cohort regarding swimming nitive function of hAPP mice, we performed MWM spatial learning and memory tests on the animals. Since path (p Ͻ 0.04; Supplemental Figure S3 at http://www. neuron.org/cgi/content/full/44/2/227/DC1) but not eshAPP mice develop cognitive deficits starting at 6 months of age, the 6.5-month-old animals in our study cape latency; however, the improvement between day 1 and day 3 or 4 was identical for both groups. All hAPP were only expected to show slight deterioration due to A␤ accumulation, when compared to nontransgenic mice taken together showed a trend toward acquiring the task quickly and reaching a plateau of performance littermates. Consistently, length of swimming path and time latency required for finding the submerged platform on day 3 when treated with CP-113,818 (p Ͻ 0.07; Figure  4 ). This could have been due to a ceiling effect owing revealed only a slight disturbance in spatial learning and memory in transgenic animals, compared to their to maximum swimming speed. Compared to placebo, the improvement between day 1 and day 3 due to CPlittermates. Clear impairment of cognitive function due to A␤ accumulation was only observed in female trans-113,818 treatment was significant (p Ͻ 0.033). As expected, CP-113,818 did not induce significant changes genic mice. In these animals, CP-113,818 treatment reversed the observed impairment in spatial learning (p Ͻ in synaptic density as assessed by synaptophysin immunoreactivity, consistent with lack of differences be-0.014; Figure 4 ). Compared to placebo, CP-113,818 treatment resulted in a significant improvement of learntween nontransgenic versus transgenic animals given their young age (Supplemental Figure S4) . Although testing between day 1 and day 3 (p Ͻ 0.016). CP-113,818 treatment did not affect spatial performance of noning of more mice at an older age will be needed to further assess the effect of decreased amyloid pathology on transgenic female mice, consistent with lack of A␤ deposition in these animals. Only on day 4, CP-113,818-spatial learning and memory, improved performance in a MWM test correlated well with the highly significant product, and its levels are indicative of changes in both decrease of overall plaque load and A␤ in CP-113,818-␣-secretase-like and ␥-secretase activities for Notch. treated female animals.
NICD levels were statistically unchanged by CP-113,818 Our previous cell-based studies have shown that treatment, when the protein was immunoprecipitated ACAT inhibition reduces A␤ generation and alters APP from nontransgenic mouse brain lysates ( Figure 5C ). processing by all three secretases (Puglielli et al., 2001) .
Similarly, levels of N-cadherin-CTF1, the product of metTo determine whether CP-113,818 treatment modified alloprotease cleavage and a substrate for ␥-secretase, brain APP processing in hAPP mice, we initially resolved were unaffected by the ACAT inhibitor ( Figure 5C ). These formic acid-extracted brain proteins by SDS-PAGE to data indicate that processing of at least two ␥-secretase detect APP and its proteolytic derivatives. Western blot substrates was not altered by CP-113,818 and that analysis showed that formic acid-extracted full-length ␣-secretase-like cleavages of these substrates were APP and APP C-terminal fragments (CTFs) C83 and C99 also unaffected. BACE protein levels were also unwere unchanged by CP-113,818. However, levels of the changed in brain lysates of CP-113,818-treated animals secreted cleavage products of both ␣-and ␤-secretases ( Figure 5D ). One mechanism that would explain our data (sAPP) were reduced by treatment with the ACAT inhibiis that ACAT inhibition may result in an interaction betor, albeit not nearly as dramatically as A␤ (Supplementween APP and an unknown protein, blocking access tal Figure S5 5A and 5B). We could not resolve C99 and C83 0.96) ( Figure 5G ). In the absence of zinc or A␤ 42 , A␤ 40 from these samples due to smearing in the low molecular alone did not significantly aggregate over 4 days (p Ͻ weight range because of high protein load ( Figure 5A ). 0.671). Together, these data show that APP-CTFs, total However, we were able to specifically detect secreted sAPP, and, to a lesser extent, sAPP␣ levels are de-APP␣ (sAPP␣), the N-terminal product of ␣-secretase creased in the brains of CP-113,818-treated nontranscleavage, in the soluble TBS fraction of the initial homoggenic mice in the absence of any apparent change in enate. sAPP␣ showed a trend toward decreasing (3.4%; the levels or processing of all control proteins tested. p Ͻ 0.14 ϭ not significant) in CP-113,818-treated aniAlthough these data, together with decreased soluble mals, while total sAPP, which also includes the ␤-secre-A␤ in hAPP mice, argue strongly that the ACAT inhibitor tase product sAPP␤, was significantly reduced by 19.1% reduces A␤ generation, they do not exclude additional (p Ͻ 0.038; Figures 5A and 5B) . A 36% decrease (p Ͻ beneficial effects of altered cholesterol metabolism on 0.013) in the ratio between total sAPP and sAPP␣ indi-A␤ aggregation, catabolism, and/or clearance. cates that inhibition of ␣-secretase in ACAT inhibitortreated mice is not as pronounced as that of other ecDiscussion todomain-shedding proteases (e.g., BACE). We next asked whether ␥-secretase component levels and ␥ acHere, we have identified a highly effective antiamyloid tivity were affected by CP-113,818 in the nontransgenic treatment in a transgenic mouse model of AD, acting brain lysates. We did not detect significant changes in via inhibition of the cholesterol-esterifying enzyme levels of PS1 N-and C-terminal fragments, nicastrin, ACAT. This treatment was gender independent in our and pen-2 ( Figure 5C Behavior Fifty-three days after the treatment, mice were trained in the MWM the test compound, but not carrier biopolymers and substances in the pellets, was released into the bloodstream. Pellets were generspatial navigation task, in which a mouse swims to find a hidden platform, using visual cues. The task is based on the principle that ated to provide either 21 days or 60 days of continuous drug delivery. For implantation of pellets, animals were anesthetized with isoflurrodents are highly motivated to escape from a water environment by the quickest, most direct route. This task is carried out in a ane. Then, sterile pellets containing either CP-113,818 or placebo were implanted subcutaneously along the anterolateral aspect of circular pool (1 m diameter) filled with water (22ЊC Ϯ 1ЊC) and virtually divided into four quadrants. A platform is placed in the southwest the left shoulder with a special precision trocar in accordance with the supplier's instructions. There was no evident need for additional quadrant 1 cm beneath the surface of the water. The computer randomly changes the starting positions of an animal. On 4 consecuhemostasis, and no signs of infection, discomfort, or distress were observed in association with the implantation and treatment.
tive days, mice attend three trials per day (each lasting for a maximum of 60 s). Escape latency (time to find the hidden platform) and length of swimming path were measured. Significant differences of Tissue Sampling the behavioral results were calculated with the Mann-Whitney U test. Animals were sacrificed the day after the last MWM training, on day 57 of treatment. Blood was obtained by cardiac puncture, and total serum was used for cholesterol determination. Transcardiac perfuWestern Blot Analysis For Western blot analyses, frozen hemispheres of nontransgenic sion with 4C PBS was performed, followed by dissection. Brains were removed, divided along the sagittal plane, and then either littermates were homogenized in TBS buffer containing 5 mM EDTA, 1 mM 1,10-phenanthroline (ICN Biomedicals), 20 M ALLN (BioMol), frozen in liquid nitrogen or immersion fixed with 4% paraformaldehyde for histologic evaluation. Liver was frozen in liquid nitrogen, and a protease inhibitor mixture (Roche). Homogenates were centrifuged at 100,000 g for 1 hr at ϩ4ЊC. The supernatants were used and adrenal glands were fixed in 4% paraformaldehyde followed by standard paraffin embedding and sectioning. Hematoxylin and for analyses of secreted APP forms and ApoE, while the pellets were extracted with the homogenization buffer containing 1% Triton eosin-stained 6-8 m sections were analyzed for evidence of CP-113,818 toxicity.
X-100 and 0.2% SDS. Total protein (120 g) was resolved on 4%-
